Aktis Oncology, Inc. (AKTS)
$25.75-$0.40 (-1.53%) Today
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 9 | 107,921 | $2.97M |
| Option exercise | 10 | 215,842 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
12 Form 4 filings on record, the earliest from Jan 12, 2026, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Ken Herrmann | Option exercise | Common Stock | 3,506 | $0.08 | $280 | |
| Ken Herrmann | Option exercise | Common Stock | 1,350 | $1.91 | $3K | |
| Ken Herrmann | Open-market sale | Common Stock | 3,506 | $24.56 | $86K | |
| Ken Herrmann | Open-market sale | Common Stock | 1,350 | $24.56 | $33K | |
| Ken Herrmann | Option exercise | Stock Option (Right to Buy) | 3,506 | $0.00 | - | |
| Ken Herrmann | Option exercise | Stock Option (Right to Buy) | 1,350 | $0.00 | - | |
| Ken Herrmann | Option exercise | Common Stock | 3,065 | $0.08 | $245 | |
| Ken Herrmann | Open-market sale | Common Stock | 3,065 | $25.21 | $77K | |
| Ken Herrmann | Option exercise | Stock Option (Right to Buy) | 3,065 | $0.00 | - | |
| Shulamit Ron-Bigger - Officer | Option exercise | Common Stock | 50,000 | $3.66 | $183K | |
| Shulamit Ron-Bigger - Officer | Open-market sale | Common Stock | 15,800 | $27.13 | $429K | |
| Shulamit Ron-Bigger - Officer | Open-market sale | Common Stock | 30,000 | $27.94 | $838K | |
| Shulamit Ron-Bigger - Officer | Open-market sale | Common Stock | 4,200 | $28.75 | $121K | |
| Shulamit Ron-Bigger - Officer | Option exercise | Stock Option (Right to Buy) | 50,000 | $0.00 | - | |
| Akos Czibere - Officer | Option exercise | Common Stock | 50,000 | $4.95 | $248K | |
| Akos Czibere - Officer | Open-market sale | Common Stock | 14,800 | $27.13 | $401K | |
| Akos Czibere - Officer | Open-market sale | Common Stock | 30,829 | $27.95 | $862K | |
| Akos Czibere - Officer | Open-market sale | Common Stock | 4,371 | $28.71 | $125K | |
| Akos Czibere - Officer | Option exercise | Stock Option (Right to Buy) | 50,000 | $0.00 | - | |
| Glenn Gormley | Grant or award | Stock Option (Right to Buy) | 37,866 | $0.00 | - | |
 Todd Foley | Other | Common Stock | 597,391 | - | - | |
| Todd Foley | Other | Common Stock | 2,688,270 | - | - | |
| Todd Foley | Other | Common Stock | 716,872 | - | - | |
| Todd Foley | Open-market purchase | Common Stock | 232,870 | $18.00 | $4.19M | |
| Todd Foley | Other | Series Seed Redeemable Convertible Preferred Stock | 2,272,727 | $0.00 | - | |
| Todd Foley | Other | Series A Redeemable Convertible Preferred Stock | 10,227,273 | $0.00 | - | |
| Todd Foley | Other | Series B Redeemable Convertible Preferred Stock | 2,727,273 | $0.00 | - | |
| MPM BIOVENTURES 2018, L.P. | Other | Common Stock | 1,314,262 | - | - | |
| MPM BIOVENTURES 2018, L.P. | Other | Common Stock | 5,914,197 | - | - | |
| MPM BIOVENTURES 2018, L.P. | Other | Common Stock | 1,577,119 | - | - | |
| MPM BIOVENTURES 2018, L.P. | Open-market purchase | Common Stock | 1,112,777 | $18.00 | $20.03M | |
| MPM BIOVENTURES 2018, L.P. | Other | Series Seed Redeemable Convertible Preferred Stock | 5,000,000 | $0.00 | - | |
| MPM BIOVENTURES 2018, L.P. | Other | Series A Redeemable Convertible Preferred Stock | 22,500,000 | $0.00 | - | |
| MPM BIOVENTURES 2018, L.P. | Other | Series B Redeemable Convertible Preferred Stock | 6,000,000 | $0.00 | - | |
| Ansbert Gadicke | Other | Common Stock | 1,314,262 | - | - | |
| Ansbert Gadicke | Other | Common Stock | 5,914,197 | - | - | |
| Ansbert Gadicke | Other | Common Stock | 1,577,119 | - | - | |
| Ansbert Gadicke | Open-market purchase | Common Stock | 1,112,777 | $18.00 | $20.03M | |
| Ansbert Gadicke | Other | Series Seed Redeemable Convertible Preferred Stock | 5,000,000 | $0.00 | - | |
| Ansbert Gadicke | Other | Series A Redeemable Convertible Preferred Stock | 22,500,000 | $0.00 | - | |
| Ansbert Gadicke | Other | Series B Redeemable Convertible Preferred Stock | 6,000,000 | $0.00 | - | |
| EcoR1 Capital, LLC - Director | Other | Common Stock | 2,270,879 | - | - | |
| EcoR1 Capital, LLC - Director | Other | Common Stock | 202,862 | - | - | |
| EcoR1 Capital, LLC - Director | Open-market purchase | Common Stock | 2,077,779 | $18.00 | $37.40M | |
| EcoR1 Capital, LLC - Director | Other | Common Stock | 128,506 | - | - | |
| EcoR1 Capital, LLC - Director | Open-market purchase | Common Stock | 144,443 | $18.00 | $2.60M | |
| EcoR1 Capital, LLC - Director | Other | Series A Redeemable Convertible Preferred Stock | 9,913,810 | - | - | |
| EcoR1 Capital, LLC - Director | Other | Series A Redeemable Convertible Preferred Stock | 997,299 | - | - | |
| EcoR1 Capital, LLC - Director | Other | Series A Redeemable Convertible Preferred Stock | 488,891 | - | - | |
| EcoR1 Capital, LLC - Director | Other | Series B Redeemable Convertible Preferred Stock | 2,397,500 | - | - | |
| EcoR1 Capital, LLC - Director | Other | Series B Redeemable Convertible Preferred Stock | 102,500 | - | - | |
| EcoR1 Capital, LLC - Director | Other | Class A Common Stock | 965,190 | - | - | |
| EcoR1 Capital, LLC - Director | Other | Class A Common Stock | 86,222 | - | - | |
| Vida Ventures II, LLC | Other | Common Stock | 4,859,370 | - | - | |
| Vida Ventures II, LLC | Open-market purchase | Common Stock | 812,455 | $18.00 | $14.62M | |
| Vida Ventures II, LLC | Open-market purchase | Common Stock | 22,545 | $18.00 | $406K | |
| Vida Ventures II, LLC | Other | Common Stock | 134,842 | - | - | |
| Vida Ventures II, LLC | Other | Series A Redeemable Convertible Preferred Stock | 14,838,250 | $0.00 | - | |
| Vida Ventures II, LLC | Other | Series A Redeemable Convertible Preferred Stock | 411,750 | $0.00 | - | |
| Vida Ventures II, LLC | Other | Series B Redeemable Convertible Preferred Stock | 3,648,750 | $0.00 | - | |
| Vida Ventures II, LLC | Other | Series B Redeemable Convertible Preferred Stock | 101,250 | $0.00 | - | |
 Helen Susan Kim | Other | Common Stock | 4,859,370 | - | - | |
| Helen Susan Kim | Open-market purchase | Common Stock | 812,455 | $18.00 | $14.62M | |
| Helen Susan Kim | Other | Common Stock | 134,842 | - | - | |
| Helen Susan Kim | Open-market purchase | Common Stock | 22,545 | $18.00 | $406K | |
| Helen Susan Kim | Other | Series A Redeemable Convertible Preferred Stock | 14,838,250 | $0.00 | - | |
| Helen Susan Kim | Other | Series A Redeemable Convertible Preferred Stock | 411,750 | $0.00 | - | |
| Helen Susan Kim | Other | Series B Redeemable Convertible Preferred Stock | 3,648,750 | $0.00 | - | |
| Helen Susan Kim | Other | Series B Redeemable Convertible Preferred Stock | 101,250 | $0.00 | - | |
 Lloyd Mitchell Segal | Other | Common Stock | 19,631 | - | - | |
| Lloyd Mitchell Segal | Other | Series A Redeemable Convertible Preferred Stock | 50,000 | $0.00 | - | |
| Lloyd Mitchell Segal | Other | Series B Redeemable Convertible Preferred Stock | 24,687 | $0.00 | - |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Aktis Oncology, Inc. (AKTS) had 4 insider filings in the last 90 days, with the most recent on 2026-07-22. The full record for AKTS runs to 12 Form 4 filings, the earliest from 2026-01-12. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of AKTS were filed in the last 90 days. 9 purchases are on record for this company.
9 insider sales of AKTS were filed in the last 90 days, totaling $2.97M.
This page tracks AKTS Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add AKTS to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
$ALARAlarum Technologies Ltd.
$ALCYAlchemy Investments Acquisition Corp 1
$ALDAltech Digital Co., Ltd.
$ALDFAldel Financial II Inc.
$ALDSAPPlife Digital Solutions Inc
$ALFCenturion Acquisition Corp.
$ALISCalisa Acquisition Corp
$ALLTAllot Ltd.
$ALMRAlamar Biosciences, Inc.
$ALOGALBERT ORIGIN ACQUISITION CorpEvery Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.